Development and current status of proton therapy for lung cancer in Korea

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The aim of this study was to examine the current status of proton therapy in Korea and to review the dosimetric benefits of proton beam therapy (PBT) over intensity-modulated radiotherapy (IMRT) for lung cancer treatment. Data from patients treated between March 2007 and February 2011 in Korea using proton therapy were analyzed retrospectively. For comparison, IMRT and PBT in the scattering mode were planned for lung cancer patients. Dosimetric benefits and organ-specific radiation-induced cancer risks were based on comparisons of dose volume histograms (DVH) and secondary radiation doses, respectively. On average, the doses delivered by PBT to the lung, esophagus and spinal cord were 17.4%, 2.5% and 43.6% of the prescription dose, respectively, which were lower than the doses delivered by IMRT (31.5%, 11.8% and 45.3%, respectively). Although the average doses delivered by PBT to the lung and spinal cord were significantly lower than those by IMRT, these differences were reduced in the esophagus. While the average secondary dose from PBT (measured at 20-50cm from the isocenter) was 1.33-0.86mSv/Gy, the average secondary dose from IMRT was 3.3-1.0mSv/Gy. Compared with IMRT techniques, PBT showed improvements in most dosimetric parameters for lung cancer patients, with lower secondary radiation doses.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalThoracic Cancer
Volume3
Issue number1
DOIs
Publication statusPublished - 2012 Feb 1
Externally publishedYes

Fingerprint

Proton Therapy
Korea
Intensity-Modulated Radiotherapy
Lung Neoplasms
Esophagus
Spinal Cord
Radiation-Induced Neoplasms
Radiation
Lung
Prescriptions

Keywords

  • Dose volume histogram
  • IMRT
  • Proton
  • Secondary dose

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Development and current status of proton therapy for lung cancer in Korea. / Yoon, Myonggeun.

In: Thoracic Cancer, Vol. 3, No. 1, 01.02.2012, p. 1-7.

Research output: Contribution to journalArticle

@article{a8dd6a12abe24df09942f43ad841c191,
title = "Development and current status of proton therapy for lung cancer in Korea",
abstract = "The aim of this study was to examine the current status of proton therapy in Korea and to review the dosimetric benefits of proton beam therapy (PBT) over intensity-modulated radiotherapy (IMRT) for lung cancer treatment. Data from patients treated between March 2007 and February 2011 in Korea using proton therapy were analyzed retrospectively. For comparison, IMRT and PBT in the scattering mode were planned for lung cancer patients. Dosimetric benefits and organ-specific radiation-induced cancer risks were based on comparisons of dose volume histograms (DVH) and secondary radiation doses, respectively. On average, the doses delivered by PBT to the lung, esophagus and spinal cord were 17.4{\%}, 2.5{\%} and 43.6{\%} of the prescription dose, respectively, which were lower than the doses delivered by IMRT (31.5{\%}, 11.8{\%} and 45.3{\%}, respectively). Although the average doses delivered by PBT to the lung and spinal cord were significantly lower than those by IMRT, these differences were reduced in the esophagus. While the average secondary dose from PBT (measured at 20-50cm from the isocenter) was 1.33-0.86mSv/Gy, the average secondary dose from IMRT was 3.3-1.0mSv/Gy. Compared with IMRT techniques, PBT showed improvements in most dosimetric parameters for lung cancer patients, with lower secondary radiation doses.",
keywords = "Dose volume histogram, IMRT, Proton, Secondary dose",
author = "Myonggeun Yoon",
year = "2012",
month = "2",
day = "1",
doi = "10.1111/j.1759-7714.2011.00085.x",
language = "English",
volume = "3",
pages = "1--7",
journal = "Thoracic Cancer",
issn = "1759-7706",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "1",

}

TY - JOUR

T1 - Development and current status of proton therapy for lung cancer in Korea

AU - Yoon, Myonggeun

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The aim of this study was to examine the current status of proton therapy in Korea and to review the dosimetric benefits of proton beam therapy (PBT) over intensity-modulated radiotherapy (IMRT) for lung cancer treatment. Data from patients treated between March 2007 and February 2011 in Korea using proton therapy were analyzed retrospectively. For comparison, IMRT and PBT in the scattering mode were planned for lung cancer patients. Dosimetric benefits and organ-specific radiation-induced cancer risks were based on comparisons of dose volume histograms (DVH) and secondary radiation doses, respectively. On average, the doses delivered by PBT to the lung, esophagus and spinal cord were 17.4%, 2.5% and 43.6% of the prescription dose, respectively, which were lower than the doses delivered by IMRT (31.5%, 11.8% and 45.3%, respectively). Although the average doses delivered by PBT to the lung and spinal cord were significantly lower than those by IMRT, these differences were reduced in the esophagus. While the average secondary dose from PBT (measured at 20-50cm from the isocenter) was 1.33-0.86mSv/Gy, the average secondary dose from IMRT was 3.3-1.0mSv/Gy. Compared with IMRT techniques, PBT showed improvements in most dosimetric parameters for lung cancer patients, with lower secondary radiation doses.

AB - The aim of this study was to examine the current status of proton therapy in Korea and to review the dosimetric benefits of proton beam therapy (PBT) over intensity-modulated radiotherapy (IMRT) for lung cancer treatment. Data from patients treated between March 2007 and February 2011 in Korea using proton therapy were analyzed retrospectively. For comparison, IMRT and PBT in the scattering mode were planned for lung cancer patients. Dosimetric benefits and organ-specific radiation-induced cancer risks were based on comparisons of dose volume histograms (DVH) and secondary radiation doses, respectively. On average, the doses delivered by PBT to the lung, esophagus and spinal cord were 17.4%, 2.5% and 43.6% of the prescription dose, respectively, which were lower than the doses delivered by IMRT (31.5%, 11.8% and 45.3%, respectively). Although the average doses delivered by PBT to the lung and spinal cord were significantly lower than those by IMRT, these differences were reduced in the esophagus. While the average secondary dose from PBT (measured at 20-50cm from the isocenter) was 1.33-0.86mSv/Gy, the average secondary dose from IMRT was 3.3-1.0mSv/Gy. Compared with IMRT techniques, PBT showed improvements in most dosimetric parameters for lung cancer patients, with lower secondary radiation doses.

KW - Dose volume histogram

KW - IMRT

KW - Proton

KW - Secondary dose

UR - http://www.scopus.com/inward/record.url?scp=84861378719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861378719&partnerID=8YFLogxK

U2 - 10.1111/j.1759-7714.2011.00085.x

DO - 10.1111/j.1759-7714.2011.00085.x

M3 - Article

VL - 3

SP - 1

EP - 7

JO - Thoracic Cancer

JF - Thoracic Cancer

SN - 1759-7706

IS - 1

ER -